Harrow, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Harrow, Inc. (HROW) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-03-02
- Harrow, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2025 was $0.00.
- Harrow, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Harrow, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $380.00K.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2023-12-31 | $380.00K 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |